title: Methylenetetrahydrofolate reductase (MTHFR) deficiency and infantile epilepsy.
abstract: OBJECTIVE
  A recessively inherited defect leading to deficiency of the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) underlies one form of hyperhomocysteinemia. We describe the association of severe MTHFR deficiency and neurological manifestations with particular attention to neurodevelopment and evolution of epileptic seizures.
  
  
  METHODS
  Case study and review of literature.
  
  
  RESULTS
  A 9 year old female infant born to Caucasian non-consanguineous parents presented with infantile spasms and developmental regression in the first year. The biochemical profile of low plasma methionine (below detectable limits), and slightly elevated homocystine (3 μmol/L (0-trace) and homocystinuria (234 μmol/gm creatinine) (0-trace amounts) was suggestive of a disturbance in homocysteine metabolism. Plasma homocysteine measurements (30.7 μmol/L, normal <13.5 μmol/L) confirmed hyperhomocysteinemia. Enzyme assay in skin fibroblasts confirmed severe MTHFR deficiency (patient 0.92, control 13.3±4.6nmol/mg/h). Molecular genetic studies identified compound heterozygosity for 2 variant polymorphisms (c.677C>T, and c.1298A>C) and a splicing mutation (c.1348+1G>A). This is a novel mutation that removes a splice site at the end of exon 7 resulting in a premature stop codon that truncates the protein, losing exons 8-11. CSF neurotransmitter analysis showed an extremely low level of 5-methyl tetrahydrofolate of <5 (40-128 nmol/L). The course of epilepsy has been characterized by progression to severe epileptic encephalopathy. Periventricular white matter change consistent with demyelination is seen on MR imaging. Treatment protocols include; oral betaine, supplementation with methionine, folic acid, and 5-methyltetrahydrofolate with questionable benefit. Epileptic seizures remain pharmacoresistant to antiepileptic medications singly and in combinations. Frequent bouts of status epilepticus have led to multiple hospitalizations, and neurosurgical interventions (corpus callosotomy, vagal nerve stimulation). At age 9 years, the patient remains severely impaired by vertebral compressive and limb fractures secondary to severe osteoporosis.
  
  
  CONCLUSIONS
  Severe MTHFR deficiency is an important diagnostic consideration in infantile epileptic encephalopathies. Early diagnosis and specific treatment interventions are possible. Further research is needed into effective treatment of epilepsy and prevention of complications in this disorder. Genotype and phenotype correlations will be explored in the light of available biochemical and molecular genetic data.
authors.affiliation: Department of Pediatrics, University of Western Ontario, London, Canada. narayan.prasad@lhsc.on.ca
authors.forename: Asuri N
authors.initials: AN
authors.lastname: Prasad
authors.forename: Charles A
authors.initials: CA
authors.lastname: Rupar
authors.forename: Chitra
authors.initials: C
authors.lastname: Prasad
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D002648:Child; D018450:Disease Progression; D004827:Epilepsy / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D005260:Female; D006712:Homocystinuria / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007223:Infant; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000172:deficiency; D009128:Muscle Spasticity / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D010375:Pedigree; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D000927:Anticonvulsants; D042965:Methylenetetrahydrofolate Reductase (NADPH2)